The study and its comparison
Fifty-nine adults with impaired glucose regulation or metabolic syndrome entered a masked, modified crossover trial. Six-month sequences compared chromium picolinate at 500 or 1,000 micrograms daily with placebo. [1]
Neither dose significantly improved the primary glucose and insulin measures. Reported secondary outcomes, including body measurements and lipids, also did not improve versus placebo. [1]
What the finding establishes
This was a modest study of metabolic measurements, not a long-term trial counting new diabetes diagnoses. It cannot validate a multi-ingredient blood-sugar product containing chromium. Funding and conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine a label lists chromium among many ingredients. This single-ingredient null trial does not demonstrate that the blend prevents diabetes.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.